Potential markers of cancer stem-like cells in ESCC: a review of the current knowledge
- PMID: 38239657
- PMCID: PMC10795532
- DOI: 10.3389/fonc.2023.1324819
Potential markers of cancer stem-like cells in ESCC: a review of the current knowledge
Abstract
In patients with esophageal squamous cell carcinoma (ESCC), the incidence and mortality rate of ESCC in our country are also higher than those in the rest of the world. Despite advances in the treatment department method, patient survival rates have not obviously improved, which often leads to treatment obstruction and cancer repeat. ESCC has special cells called cancer stem-like cells (CSLCs) with self-renewal and differentiation ability, which reflect the development process and prognosis of cancer. In this review, we evaluated CSLCs, which are identified from the expression of cell surface markers in ESCC. By inciting EMTs to participate in tumor migration and invasion, stem cells promote tumor redifferentiation. Some factors can inhibit the migration and invasion of ESCC via the EMT-related pathway. We here summarize the research progress on the surface markers of CSLCs, EMT pathway, and the microenvironment in the process of tumor growth. Thus, these data may be more valuable for clinical applications.
Keywords: EMT; cancer stem-like cells; esophageal squamous cell carcinoma; microenvironment; surface markers.
Copyright © 2024 Wang, Liu, Liu, Guo, Yan, Chen, Wu, Xu, Zhou, Liu, Peng, Cheng and Yan.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
Cripto-1 acts as a functional marker of cancer stem-like cells and predicts prognosis of the patients in esophageal squamous cell carcinoma.Mol Cancer. 2017 Apr 21;16(1):81. doi: 10.1186/s12943-017-0650-7. Mol Cancer. 2017. PMID: 28431580 Free PMC article.
-
EGFR inhibitors prevent induction of cancer stem-like cells in esophageal squamous cell carcinoma by suppressing epithelial-mesenchymal transition.Cancer Biol Ther. 2015;16(6):933-40. doi: 10.1080/15384047.2015.1040959. Epub 2015 Apr 21. Cancer Biol Ther. 2015. PMID: 25897987 Free PMC article.
-
The Role of β-Arrestin1 in Esophageal Squamous Cell Carcinoma.Onco Targets Ther. 2020 Mar 3;13:1873-1881. doi: 10.2147/OTT.S235066. eCollection 2020. Onco Targets Ther. 2020. PMID: 32184622 Free PMC article.
-
Upregulation of Fucosyltransferase 3, 8 and protein O-Fucosyltransferase 1, 2 genes in esophageal cancer stem-like cells (CSLCs).Glycoconj J. 2020 Jun;37(3):319-327. doi: 10.1007/s10719-020-09917-z. Epub 2020 Mar 10. Glycoconj J. 2020. PMID: 32157457
-
3,3'-Diindolylmethane modulates aryl hydrocarbon receptor of esophageal squamous cell carcinoma to reverse epithelial-mesenchymal transition through repressing RhoA/ROCK1-mediated COX2/PGE2 pathway.J Exp Clin Cancer Res. 2020 Jun 16;39(1):113. doi: 10.1186/s13046-020-01618-7. J Exp Clin Cancer Res. 2020. PMID: 32546278 Free PMC article.
Cited by
-
Unlocking ESCC Progression: CCL15-CCR1 Axis Activates AKT/ERK1/2/c-Jun/CDK2 Pathway.J Cancer. 2025 Jul 4;16(10):3112-3127. doi: 10.7150/jca.113925. eCollection 2025. J Cancer. 2025. PMID: 40740234 Free PMC article.
-
TOM1L1 mediated the sort of tumor suppressive miR-378a-3p into exosomes and the excretion out of cells to promote ESCC progression.Cancer Gene Ther. 2025 May;32(5):507-520. doi: 10.1038/s41417-025-00889-6. Epub 2025 Mar 23. Cancer Gene Ther. 2025. PMID: 40123000
-
Downregulation of SMAD2 and SMAD4 is associated with poor prognosis and shorter survival in esophageal squamous cell carcinoma.Mol Biol Rep. 2025 Mar 3;52(1):274. doi: 10.1007/s11033-025-10390-w. Mol Biol Rep. 2025. PMID: 40029457
-
The Role of GREMLIN1, a Bone Morphogenetic Protein Antagonist, in Cancer Stem Cell Regulation.Cells. 2025 Apr 11;14(8):578. doi: 10.3390/cells14080578. Cells. 2025. PMID: 40277903 Free PMC article. Review.
References
Publication types
LinkOut - more resources
Full Text Sources